CA3087090A1 - Dry powder ketamine composition for use in the treatment of depression by pulmonary administration - Google Patents

Dry powder ketamine composition for use in the treatment of depression by pulmonary administration Download PDF

Info

Publication number
CA3087090A1
CA3087090A1 CA3087090A CA3087090A CA3087090A1 CA 3087090 A1 CA3087090 A1 CA 3087090A1 CA 3087090 A CA3087090 A CA 3087090A CA 3087090 A CA3087090 A CA 3087090A CA 3087090 A1 CA3087090 A1 CA 3087090A1
Authority
CA
Canada
Prior art keywords
ketamine
composition
esketamine
dose
dry powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3087090A
Other languages
English (en)
French (fr)
Inventor
Maciej Wieczorek
Ewa TRATKIEWICZ
Przemyslaw PERKO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celon Pharma SA
Original Assignee
Celon Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma SA filed Critical Celon Pharma SA
Publication of CA3087090A1 publication Critical patent/CA3087090A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA3087090A 2017-12-29 2018-09-28 Dry powder ketamine composition for use in the treatment of depression by pulmonary administration Pending CA3087090A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17461651.6A EP3505157B1 (en) 2017-12-29 2017-12-29 Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
PCT/EP2018/076394 WO2019129397A1 (en) 2017-12-29 2018-09-28 Dry powder ketamine composition for use in the treatment of depression by pulmonary administration
EP17461651.6 2020-12-29

Publications (1)

Publication Number Publication Date
CA3087090A1 true CA3087090A1 (en) 2019-07-04

Family

ID=60915417

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3087090A Pending CA3087090A1 (en) 2017-12-29 2018-09-28 Dry powder ketamine composition for use in the treatment of depression by pulmonary administration

Country Status (16)

Country Link
US (3) US20200337999A1 (https=)
EP (2) EP3505157B1 (https=)
JP (1) JP7315556B2 (https=)
KR (2) KR102763099B1 (https=)
CN (1) CN111818912A (https=)
AU (2) AU2018395791B2 (https=)
BR (1) BR112020013282A2 (https=)
CA (1) CA3087090A1 (https=)
DK (2) DK3505157T3 (https=)
EA (1) EA202091618A1 (https=)
ES (2) ES2907692T3 (https=)
HU (2) HUE058320T2 (https=)
MX (1) MX2020006900A (https=)
PL (2) PL3505157T3 (https=)
PT (2) PT3505157T (https=)
WO (1) WO2019129397A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
CN110868601B (zh) 2018-08-28 2024-03-15 华为技术有限公司 帧间预测方法、装置以及视频编码器和视频解码器
EP3628313B1 (en) * 2018-09-28 2025-02-12 Novohale Therapeutics, LLC Ketamine composition for use in a method of treatment of depression by pulmonary administration
CN115418398B (zh) * 2022-08-30 2025-02-18 广州医科大学附属脑科医院 一组用于预测氯胺酮治疗难治性抑郁症的疗效的标志物及其应用

Family Cites Families (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69629108T2 (de) * 1995-02-24 2004-04-22 Weg, Stuart L. Anwendung von ketamin zur entgiftung
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
US20050148673A1 (en) 2002-07-11 2005-07-07 Harbut Ronald E. Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
AU2003268026A1 (en) 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
AU2003291037A1 (en) * 2002-11-18 2004-06-15 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
ATE433993T1 (de) 2003-02-26 2009-07-15 Univ Johns Hopkins Modulatorische verbindungen und verfahren für glutamattransport
AU2004229551A1 (en) 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
MXPA06011891A (es) 2004-04-20 2007-04-24 Pfizer Metodo para tratar el dolor neuropatico.
US20060240043A1 (en) 2004-10-08 2006-10-26 Meyerson Laurence R Methods and compositions for treating migraine pain
US20080096872A1 (en) 2004-12-22 2008-04-24 Friedman Robert S Composition for Treatment of Pain Specification
EP1855686A1 (en) 2005-03-01 2007-11-21 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain
JP2008531158A (ja) 2005-03-04 2008-08-14 メンティス キュラ イーエイチエフ． 神経学的状態を評価する方法および系
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
KR101529318B1 (ko) 2005-12-19 2015-06-16 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
WO2007111880A2 (en) * 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
US20090306137A1 (en) 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
EP1902733A1 (en) 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
AU2008279572A1 (en) 2007-02-01 2009-01-29 David Chau Combinations of dopamine D2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
WO2008140859A1 (en) 2007-03-15 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
WO2008141057A1 (en) 2007-05-08 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
US20100316678A1 (en) 2007-06-28 2010-12-16 Cnsbio Pty Ltd. Combination methods and compositions for treatment of neuropathic pain
US7828771B2 (en) 2007-07-26 2010-11-09 Entra Pharmaceuticals, Inc. Systems and methods for delivering drugs
WO2009021058A2 (en) 2007-08-06 2009-02-12 Trinity Labortories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
JP2010540454A (ja) 2007-09-21 2010-12-24 アカディア ファーマシューティカルズ，インコーポレーテッド ピマバンセリンと他の薬剤との併用投与
US20100297181A1 (en) 2007-12-26 2010-11-25 Eisai R&D Management Co., Ltd. AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
US20090198145A1 (en) 2008-02-06 2009-08-06 Chow Harrison Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
US20140037718A1 (en) 2009-03-06 2014-02-06 George W. Lutz Transdermal pain gel
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
DK3254676T3 (en) 2009-10-30 2019-03-11 Ix Biopharma Ltd QUICK-SOLVING SOLID DOSAGE FORM
CN107468211A (zh) 2010-01-18 2017-12-15 艾欧敏达有限公司 用于分析神经生理学数据的方法和系统以及评估系统
WO2013003669A2 (en) 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
JP2015501652A (ja) 2011-12-14 2015-01-19 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｇａｂｒ−ａ２診断
PE20141906A1 (es) 2012-03-12 2014-12-05 Janssen Pharmaceutica Nv Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
EP2830604A4 (en) 2012-03-30 2015-08-19 Gen Hospital Corp COMPOSITIONS WITH SCOPOLAMINE AND KETAMINE FOR THE TREATMENT OF DEPRESSIONS
US20120323214A1 (en) 2012-05-16 2012-12-20 Totada R Shantha Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis
WO2014020155A1 (en) 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
JP6722453B2 (ja) 2012-08-23 2020-07-15 スチュアート エル ウェグ 抗不安薬組成物、製剤および使用方法
US8974365B2 (en) 2012-11-25 2015-03-10 Steven Richard Devore Best Treatment of thalamocortical dysrhythmia
WO2014100501A1 (en) 2012-12-20 2014-06-26 Sanford-Burnham Medical Research Institute Small molecule agonists of neurotensin receptor 1
CN116251084A (zh) 2013-03-15 2023-06-13 詹森药业有限公司 S-盐酸氯胺酮的药物组合物
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
JP6473738B2 (ja) 2013-04-01 2019-02-20 パルマトリックス，インコーポレイテッド チオトロピウム乾燥粉末
US9913803B2 (en) 2013-08-26 2018-03-13 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
SI3043785T1 (sl) 2013-09-13 2022-02-28 National University Corporation Chiba University Uporaba R-ketamina in njegove soli kot farmacevtska sredstva
CA2936809A1 (en) 2014-01-14 2015-07-23 Children's Hospital Medical Center Compositions comprising ketamine for treating an autism spectrum disorder
DK3272338T3 (da) 2014-04-17 2020-11-02 Develco Pharma Schweiz Ag Oral doseringsform for ketamin
KR20170013890A (ko) 2014-05-06 2017-02-07 노쓰웨스턴유니버시티 Nmdar 조절 화합물의 조합물
US11207316B2 (en) 2014-05-30 2021-12-28 West Virginia University Ketamine or dextromethorphan formulations and methods of use
US20160008777A1 (en) 2014-07-09 2016-01-14 Novotec Consulting Inc. Pharmaceutical compounding kit
CN106714789A (zh) 2014-08-13 2017-05-24 詹森药业有限公司 用于治疗抑郁症的方法
CN107208133A (zh) 2014-09-15 2017-09-26 詹森药业有限公司 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法
KR20170095807A (ko) 2014-10-07 2017-08-23 램 테라퓨틱스, 인코포레이티드 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제
AU2015343083B2 (en) 2014-11-04 2020-07-23 Acadia Pharmaceuticals Inc. Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods
JP6696994B2 (ja) 2014-12-08 2020-05-20 クレシオ・バイオサイエンシズ・リミテッド 即放性乱用抑止性顆粒剤形
WO2016109427A1 (en) 2014-12-31 2016-07-07 Icahn School Of Medicine At Mount Sinai Method of maintaining the anti-depressant effect of ketamine with lithium
WO2016112467A1 (en) 2015-01-15 2016-07-21 Centre For Addiction And Mental Health Peripheral measure of central brain inflammation, markers therefor and uses thereof
EP3085366A1 (en) 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
WO2016186968A1 (en) 2015-05-15 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating motor disorders
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
WO2016201299A1 (en) 2015-06-12 2016-12-15 Indiana University Research & Technology Corporation Predicting suicidality using a combined genomic and clinical risk assessment
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用
JP2018530593A (ja) 2015-10-16 2018-10-18 ノースウェスタン ユニバーシティ 統合失調症、双極性障害、認知障害及び大うつ病性障害の治療のための非定型的抗精神病薬ならびにｎｍｄａ調節剤の医薬品の組み合わせ
US10881637B2 (en) 2015-11-17 2021-01-05 Atlee Solomon Intranasal and transdermal administration of kappa-opioid-receptor agonists: salvinorin A for the treatment of neuropsychiatric and addictive disorders
EP3377050A4 (en) 2015-11-17 2019-11-20 The Trustees of Columbia University in the City of New York PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS
US20180296478A1 (en) 2016-02-12 2018-10-18 Synergistic Therapeutics, Llc Sublingual antidepressant and antianxiety tablet
US20180042936A1 (en) 2016-03-18 2018-02-15 Genomind, Inc. Maintenance therapy using tianeptine
CA3019012A1 (en) 2016-03-25 2017-09-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
US11213495B2 (en) 2016-05-25 2022-01-04 National Health Research Institutes Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine
JP7556688B2 (ja) 2016-07-28 2024-09-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｇｐｒ１５６変異体及びその使用
WO2018025089A2 (en) 2016-08-05 2018-02-08 Shin Nippon Biomedical Laboratories, Ltd. Pharmaceutical compositions
US20180064655A1 (en) 2016-09-06 2018-03-08 Steven Sounyoung Yu Hydroxynorketamine Transdermal Patch
US10596378B2 (en) 2016-10-18 2020-03-24 Joseph Rustick Method for treatment of depression using synaptic pathway training
US10905897B2 (en) 2016-10-20 2021-02-02 Neuro-Laser Foundation, Inc. Synergistic treatment methodologies using light therapy
US20190240184A1 (en) 2016-10-27 2019-08-08 National University Corporation Chiba University Pharmaceutical applications for (s)-norketamine and salts thereof
US20180177744A1 (en) 2016-12-22 2018-06-28 Gary Jay Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine
US20180177743A1 (en) 2016-12-22 2018-06-28 Gary Jay Method of treating pain using racemic mixture of s-ketamine and r-ketamine
CN110913844A (zh) 2017-04-20 2020-03-24 广州大洲生物医药科技有限公司 用于氯胺酮的透皮药物递送系统
CA3105451A1 (en) 2017-05-12 2018-11-15 Indiana University Research And Technology Corporation Precision medicine for treating and preventing suicidality
RU2019143572A (ru) 2017-05-25 2021-06-25 Глитек Ллс. Композиции для лечения посттравматического стрессового расстройства
DE102017112527B4 (de) 2017-06-07 2019-01-03 Lts Lohmann Therapie-Systeme Ag Schnell zerfallende Schaumwafer mit hohem Flächengewicht
EP3641742B1 (en) 2017-06-23 2026-03-25 Ketabon GmbH Hydroxynorketamine for the use in the treatment of depression
US11331270B2 (en) 2017-08-20 2022-05-17 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
ES2924188T3 (es) 2017-09-25 2022-10-05 Small Pharma Ltd Formas sólidas de dosificación oral de derivados de ketamina
WO2019065900A1 (ja) 2017-09-27 2019-04-04 国立大学法人千葉大学 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体
EP3698260A4 (en) 2017-10-19 2021-08-04 Eleusis Health Solutions US, Inc. METHODS AND SYSTEMS FOR INCREASING THE SAFETY OF AWARENESS-ENHANCING DRUG THERAPIES
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
WO2019099568A1 (en) 2017-11-14 2019-05-23 Bexson Biomedical, Inc. Systems, devices, formulations and methods for controlled drug delivery
DE102017129012A1 (de) 2017-12-06 2019-06-06 Lts Lohmann Therapie-Systeme Ag Oraler Dünnfilm mit hoher Wirkstoffbeladung
MX2020006650A (es) 2017-12-22 2020-11-06 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
IL275968B2 (en) 2018-01-10 2024-07-01 Xwpharma Ltd Prodrugs of ketamine, compositions and uses thereof
AU2019223014B2 (en) 2018-02-21 2024-10-17 Orphai Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
WO2019186357A1 (en) 2018-03-26 2019-10-03 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
US20230390385A1 (en) 2018-04-11 2023-12-07 Fred M. COWAN Compositions and Methods for Prevention and Treatment of Immune Complex Disease
AU2019262197B2 (en) 2018-05-04 2024-12-19 Perception Neuroscience, Inc. Methods of treating substance abuse
CN112469396A (zh) 2018-05-31 2021-03-09 昆士兰大学 核壳聚合物纳米颗粒
GB201809976D0 (en) 2018-06-18 2018-08-01 Neurocentrx Pharma Ltd Novel formulations
PL3813802T3 (pl) 2018-06-27 2025-04-22 Bioxcel Therapeutics, Inc. Formulacje błony zawierające deksmedetomidynę i sposoby ich wytwarzania
JP2021529732A (ja) 2018-06-27 2021-11-04 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害の処置方法
US12005142B2 (en) 2018-08-02 2024-06-11 Taiwan Liposome Co., Ltd. Sustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof
US20200038420A1 (en) 2018-08-03 2020-02-06 Enterin, Inc. Aminosterol compositions and methods of using the same for treating depression
US11154537B2 (en) 2018-08-10 2021-10-26 Eleusis Therapeutics Us, Inc. Method of treatment for ketamine infusion
US12090145B2 (en) 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases
EP3628313B1 (en) 2018-09-28 2025-02-12 Novohale Therapeutics, LLC Ketamine composition for use in a method of treatment of depression by pulmonary administration
US20210113494A1 (en) 2018-10-05 2021-04-22 Clexio Biosciences Ltd. Method Of Treating Post-Traumatic Stress Syndrome
WO2020086673A1 (en) 2018-10-26 2020-04-30 Guangzhou Dazhou Biomedicine Ltd. Ketamine oral transmucosal delivery system
WO2020089897A1 (en) 2018-10-29 2020-05-07 Hadasit Medical Research Services & Development Limited Combination of m-opioid receptor (mor) modulators for preventing and treating pain, suicidality and mental disorders
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
HRP20240255T1 (hr) 2019-01-11 2024-05-24 Alar Pharmaceuticals Inc. Ketamin pamoat i njegova uporaba
CA3127607A1 (en) 2019-01-23 2020-07-30 The Regents Of The University Of Michigan Pharmacogenomic decision support for modulators of the nmda, glycine, and ampa receptors
WO2020168213A1 (en) 2019-02-15 2020-08-20 Massachusetts Institute Of Technology Methods for evaluating treatments and physiology in human patients using intravenous alpha-2 adrenergic antagonist agents
MX2021010683A (es) 2019-03-05 2021-12-10 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
EP4219498A1 (en) 2019-03-07 2023-08-02 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
US12551533B2 (en) 2019-03-18 2026-02-17 New York Medical College Intranasal neuropeptides for use in stress-related impairments
US20220241218A1 (en) 2019-04-17 2022-08-04 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system
WO2020223701A1 (en) 2019-05-02 2020-11-05 The Broad Institute, Inc. Methods for treating neurodevelopmental disorders
US12589083B2 (en) 2019-05-07 2026-03-31 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2020225774A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Dosage forms for preventing drug-facilitated assault
BR112021024138A2 (pt) 2019-05-31 2022-01-11 Celon Pharma Sa Sistema para administração supervisionada eletronicamente de uma composição farmacêutica
CN113905777B (zh) 2019-05-31 2025-06-20 赛隆制药股份公司 用于电子监督胃肠外施用药物组合物的吸入器
US12502363B2 (en) 2019-06-04 2025-12-23 ADNP Kids Research Foundation Ketamine and ketamine/nap for treatment of ADNP syndrome and related neurological conditions
EP3923920A4 (en) 2019-08-05 2022-11-23 The Ketamine Research Foundation KETAMINE FOR THE TREATMENT OF SYMPTOMS AND DISORDERS AFTER CHILDREN
US20220304950A1 (en) 2019-08-28 2022-09-29 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of patients with major depressive disorder, including suicidality
GB201912505D0 (en) 2019-08-30 2019-10-16 Klaria Pharma Holding Ab Pharmaceutical formulation
US20220339123A1 (en) 2019-09-13 2022-10-27 Janssen Pharmaceuticals, Inc. Intranasal administration of esketamine
EP4041226A1 (en) 2019-10-02 2022-08-17 Praxis Precision Medicines, Inc. Combinations of gaba-a receptor positive allosteric modulators and nmda antagonists, nmda negative allosteric modulators or nmda partial agonists
CA3156658A1 (en) 2019-10-18 2021-04-22 Institute Of Science And Technology Austria NEURONAL PLASTICITY STIMULATION
WO2021087258A1 (en) 2019-10-31 2021-05-06 The Trustees Of Indiana University Compositions and methods for treating alcohol use disorder or a related condition thereof
WO2021108801A2 (en) 2019-11-15 2021-06-03 Consegna Pharma, Inc. Long acting nmda antagonists
JP2023503271A (ja) 2019-11-18 2023-01-27 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ （２ｒ，６ｒ）－ヒドロキシノルケタミンの塩、それらの結晶形、およびその製造方法
CA3158059A1 (en) 2019-11-19 2021-05-27 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
EP4076410B1 (en) 2019-12-20 2025-09-10 Alar Pharmaceuticals Inc. Long-acting injectable formulations of ketamine pamoate salts
WO2021137147A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
PH12022551856A1 (en) 2020-01-22 2024-01-03 Seelos Therapeutics Inc Reducing side effects of nmda antagonists
DE102020106115A1 (de) 2020-03-06 2021-09-09 Lts Lohmann Therapie-Systeme Ag Iontophoretische Zusammensetzung zur Verabreichung von S-Ketamin
WO2021207349A1 (en) 2020-04-07 2021-10-14 Joseph Habboushe Prevention and treatment of virial infections
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
US20230210789A1 (en) 2020-06-02 2023-07-06 Ix Biopharma Limited Methods for treating major depressive disorder and treatment-resistant depression
TW202214218A (zh) 2020-06-19 2022-04-16 大陸商廣州大洲生物醫藥科技有限公司 氯胺酮的透皮給藥系統
US20210401774A1 (en) 2020-06-27 2021-12-30 Robert Brent Turnipseed Ketamine protocols and data evaluation for treatment-resistant depression and trauma
US20220001014A1 (en) 2020-07-01 2022-01-06 Lida Ghaderi Compositions and methods for inducing biological mimicry in a mammal for the prevention and/or treatment of covid-19 and other diseases
US20220040106A1 (en) 2020-08-05 2022-02-10 Thomas Malcolm Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
EP3949956A1 (en) 2020-08-06 2022-02-09 LTS Lohmann Therapie-Systeme AG Esketamine-suspension-tts
JP7814375B2 (ja) 2020-08-18 2026-02-16 オークウッド ラボラトリーズ，エル．エル．シー． ケタミンを含むマイクロスフェア製剤ならびにその製造及び使用方法
US20230375561A1 (en) 2020-09-30 2023-11-23 Rima F. Kaddurah-Daouk Methods for identification, stratification, and treatment of cns diseases
US20230404914A1 (en) 2020-11-09 2023-12-21 Lts Lohmann Thereapie-Systeme Ag Oral thin film
WO2022109165A1 (en) 2020-11-18 2022-05-27 Indiana University Research And Technology Corporation Methods for objective assessment, risk prediction, matching to existing medications and new methods of using drugs, and monitoring responses to treatments for mood disorders
US11382873B1 (en) 2021-01-08 2022-07-12 Vitalis Analgesics LLC Oral administration of ketamine
IL282188A (en) 2021-04-08 2022-11-01 Yeda Res & Dev Combined use of ketamine and bretigabine for the treatment of psychiatric disorders
WO2023018966A1 (en) 2021-08-13 2023-02-16 XWPharma Ltd. Pharmaceutical compositions and oral dosage forms of ketamine derivatives
WO2023081109A1 (en) 2021-11-05 2023-05-11 Malcolm Thomas Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
WO2024010935A1 (en) 2022-07-07 2024-01-11 Vitalis Analgesics LLC Compositions of aspirin and ketamine

Also Published As

Publication number Publication date
KR20250024526A (ko) 2025-02-18
JP7315556B2 (ja) 2023-07-26
US12440440B2 (en) 2025-10-14
EP3505157A1 (en) 2019-07-03
JP2021510682A (ja) 2021-04-30
PL3731815T3 (pl) 2022-04-11
KR20200105857A (ko) 2020-09-09
KR102763099B1 (ko) 2025-02-05
ES2907692T3 (es) 2022-04-26
AU2025201057A1 (en) 2025-03-06
EP3731815A1 (en) 2020-11-04
BR112020013282A2 (pt) 2020-12-01
US20200337999A1 (en) 2020-10-29
CN111818912A (zh) 2020-10-23
AU2018395791A1 (en) 2020-07-16
EP3505157B1 (en) 2021-12-08
DK3731815T3 (da) 2022-02-28
DK3505157T3 (da) 2022-02-28
HUE058099T2 (hu) 2022-07-28
US20250090457A1 (en) 2025-03-20
WO2019129397A1 (en) 2019-07-04
PL3505157T3 (pl) 2022-04-11
MX2020006900A (es) 2020-11-09
EP3731815B1 (en) 2021-12-08
AU2018395791B2 (en) 2024-11-28
PT3505157T (pt) 2022-02-18
US20250170059A1 (en) 2025-05-29
EA202091618A1 (ru) 2021-03-17
PT3731815T (pt) 2022-02-15
ES2907781T3 (es) 2022-04-26
HUE058320T2 (hu) 2022-07-28

Similar Documents

Publication Publication Date Title
US12440440B2 (en) Dry powder esketamine composition for use in the treatment of bipolar depression by pulmonary administration
US20220230723A1 (en) Electronically Supervised Administration of a Pharmaceutical Composition
EP3976145B1 (en) An inhaler for electronically supervised parenteral administration of a pharmaceutical composition
AU2019349624B2 (en) Ketamine composition for use in a method of treatment of depression by pulmonary administration
EA044969B1 (ru) Композиция кетамина для применения в способе лечения депрессии путём ингаляционного введения
EA046690B1 (ru) Композиция кетамина в виде сухого порошка для применения при лечении депрессии ингаляционным путем
AU2013100007A4 (en) System for treating chronic obstructive pulmonary disease
AU2013100008B4 (en) Inhalable formulations of glycopyrronium bromide

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220926

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240902

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240902

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240902

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241015

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20250110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250110

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250221

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250614

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250703

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250703

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250704

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250704

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260324

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260324